Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson… Read more
Prothena Corporation plc (PRTA) - Net Assets
Latest net assets as of September 2025: $294.99 Million USD
Based on the latest financial reports, Prothena Corporation plc (PRTA) has net assets worth $294.99 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($352.63 Million) and total liabilities ($57.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $294.99 Million |
| % of Total Assets | 83.65% |
| Annual Growth Rate | 83.39% |
| 5-Year Change | 164.63% |
| 10-Year Change | 35.01% |
| Growth Volatility | 1747.52 |
Prothena Corporation plc - Net Assets Trend (2010–2024)
This chart illustrates how Prothena Corporation plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Prothena Corporation plc (2010–2024)
The table below shows the annual net assets of Prothena Corporation plc from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $486.93 Million | -13.26% |
| 2023-12-31 | $561.37 Million | -9.75% |
| 2022-12-31 | $622.04 Million | +33.47% |
| 2021-12-31 | $466.04 Million | +153.28% |
| 2020-12-31 | $184.01 Million | -32.58% |
| 2019-12-31 | $272.92 Million | -15.50% |
| 2018-12-31 | $323.00 Million | -20.68% |
| 2017-12-31 | $407.19 Million | +11.44% |
| 2016-12-31 | $365.40 Million | +1.31% |
| 2015-12-31 | $360.67 Million | +24.42% |
| 2014-12-31 | $289.89 Million | +67.30% |
| 2013-12-31 | $173.27 Million | +36.99% |
| 2012-12-31 | $126.48 Million | +2065.26% |
| 2011-12-31 | $-6.44 Million | -6536.00% |
| 2010-12-31 | $100.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prothena Corporation plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 108984100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $538.00K | 0.11% |
| Other Components | $1.59 Billion | 326.28% |
| Total Equity | $486.93 Million | 100.00% |
Prothena Corporation plc Competitors by Market Cap
The table below lists competitors of Prothena Corporation plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Adaptive Plasma Technology Corp
KQ:089970
|
$390.64 Million |
|
Longmaster Information Tech
SHE:300288
|
$390.69 Million |
|
Grindr Inc
NYSE:GRND
|
$390.77 Million |
|
AB Dynamics plc
PINK:ABDDF
|
$390.81 Million |
|
ZKTECO Co. Ltd. A
SHE:301330
|
$390.47 Million |
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
$390.32 Million |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
$390.05 Million |
|
361 Degrees International Limited
PINK:TSIOF
|
$390.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prothena Corporation plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 561,365,000 to 486,926,000, a change of -74,439,000 (-13.3%).
- Net loss of 122,310,000 reduced equity.
- Share repurchases of 353,000 reduced equity.
- Other factors increased equity by 48,224,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-122.31 Million | -25.12% |
| Share Repurchases | $353.00K | -0.07% |
| Other Changes | $48.22 Million | +9.9% |
| Total Change | $- | -13.26% |
Book Value vs Market Value Analysis
This analysis compares Prothena Corporation plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.99x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1591.11x to 0.99x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $0.01 | $9.00 | x |
| 2011-12-31 | $-0.36 | $9.00 | x |
| 2012-12-31 | $8.67 | $9.00 | x |
| 2013-12-31 | $9.31 | $9.00 | x |
| 2014-12-31 | $11.75 | $9.00 | x |
| 2015-12-31 | $11.89 | $9.00 | x |
| 2016-12-31 | $10.64 | $9.00 | x |
| 2017-12-31 | $10.81 | $9.00 | x |
| 2018-12-31 | $8.16 | $9.00 | x |
| 2019-12-31 | $6.84 | $9.00 | x |
| 2020-12-31 | $4.61 | $9.00 | x |
| 2021-12-31 | $9.62 | $9.00 | x |
| 2022-12-31 | $13.13 | $9.00 | x |
| 2023-12-31 | $10.55 | $9.00 | x |
| 2024-12-31 | $9.06 | $9.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prothena Corporation plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -90.49%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.12x
- Recent ROE (-25.12%) is above the historical average (-855.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -12482.00% | -1004.18% | 0.38x | 33.00x | $-12.49 Million |
| 2011 | 0.00% | -5852.07% | 0.14x | 0.00x | $-29.03 Million |
| 2012 | -32.74% | -1557.98% | 0.02x | 1.02x | $-54.06 Million |
| 2013 | -23.66% | -6064.50% | 0.00x | 1.05x | $-58.32 Million |
| 2014 | -2.47% | -14.06% | 0.17x | 1.05x | $-36.14 Million |
| 2015 | -22.35% | -5016.30% | 0.00x | 1.07x | $-116.68 Million |
| 2016 | -43.82% | -15176.11% | 0.00x | 1.26x | $-196.65 Million |
| 2017 | -37.63% | -556.84% | 0.06x | 1.22x | $-193.96 Million |
| 2018 | -48.19% | -16297.91% | 0.00x | 1.54x | $-187.94 Million |
| 2019 | -28.46% | -9542.63% | 0.00x | 1.54x | $-104.97 Million |
| 2020 | -60.40% | -13029.78% | 0.00x | 1.81x | $-129.54 Million |
| 2021 | 14.37% | 33.39% | 0.33x | 1.31x | $20.37 Million |
| 2022 | -18.80% | -216.95% | 0.07x | 1.22x | $-179.15 Million |
| 2023 | -26.19% | -160.91% | 0.13x | 1.24x | $-203.16 Million |
| 2024 | -25.12% | -90.49% | 0.25x | 1.12x | $-171.00 Million |
Industry Comparison
This section compares Prothena Corporation plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prothena Corporation plc (PRTA) | $294.99 Million | -12482.00% | 0.20x | $390.53 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |